1201709115_133b3927a3_b

Bayer and Exscientia to work together on AI in cardiovascular and oncology drug discovery

pharmafile | January 10, 2020 | News story | Medical Communications Bayer, Exscientia, oncology 

Bayer AG has partnered with Exscientia to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology.

Dr. Joerg Moeller, Member of the Executive Committee of Bayer AG’s Pharmaceuticals Division and Head of Research and Development, said: “The collaboration with Exscientia is expected to help us to achieve project milestones earlier and at the same time accelerate timelines by enabling more precise identification of suitable drug targets and lead structures.”

Exscientia, a leading AI drug discovery company, will apply its Centaur Chemist AI drug discovery platform to discover and optimise drug candidates. Exscientia will initially work on three projects, with the targets agreed between them and Bayer.

Advertisement

Exescientia may be eligible to receive €240 million. This could include research payments and sales royalties.

Professor Andrew Hopkins, Chief Executive Officer of Exscientia, said: “We’re delighted to collaborate with Bayer, a globally recognised pharmaceutical company. Since our pioneering Nature papers demonstrating the automated design of small molecules, we have enhanced our platform and exemplified it commercially, by accelerating the discovery of future drug molecules with partners.” 

Conor Kavanagh

 

Related Content

Evotec and Bayer announce new kidney disease study

Evotec and Bayer have announced the initiation of a phase 2 clinical study in kidney …

Rethinking oncology trial endpoints with generalised pairwise comparisons

For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …

drug-trials

Pharma&’s ovarian cancer therapy approved for use by NHS Scotland

Pharma& has announced that its treatment for ovarian cancer, Rubraca (rucaparib), has been accepted by …

The Gateway to Local Adoption Series

Latest content